Gallium-67 scintigraphy in right ventricular disease

Published: 02-10-2007
Last updated: 09-05-2024

To study whether inflammmation plays a role in patients with RV disease, and can be detected with Gallium-67 scintigraphy

Ethical review	Approved WMO
Status	Pending
Health condition type	Congenital cardiac disorders
Study type	Observational invasive

Summary

ID

NL-OMON31115

Source
ToetsingOnline

Brief title
Gallium-RV scintigraphy

Condition

- Congenital cardiac disorders
- Cardiac and vascular disorders congenital
- Pulmonary vascular disorders

Synonym
right ventricular disease, right ventricular failure

Research involving
Human

Sponsors and support

Primary sponsor: Universitair Medisch Centrum
Source(s) of monetary or material Support: Ministerie van OC&W

Intervention

Keyword: Brugada syndrome, chronic thromboembolic pulmonary hypertension, congenital heart disease, right ventricular disease

Outcome measures

Primary outcome

The proportion of positive scintigrams is related to disease severity in each

group.

Secondary outcome

none

Study description

Background summary

Right ventricular (RV) disease cannot be adequately treated, as its pathophysiology is unknown. New insights indicate that inflammation may play a role.

Study objective

To study whether inflammmation plays a role in patients with RV disease, and can be detected with Gallium-67 scintigraphy

Study design

A single Gallium-67 scintigram is conducted.

Study burden and risks

Risk is negligable (Gallium-67 scintigraphy is routinely used in clinical practice, e.g., in cardiac disease)

Burden is limited: intravenous injection and 1 extra hospital visit, total duration 60 min.

Contacts

Public
Selecteer

AMC, Meibergdreef 9
1105 AZ Amsterdam
NL
Scientific
Selecteer

AMC, Meibergdreef 9
1105 AZ Amsterdam
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

right ventricular dysfunction

Exclusion criteria

pregnancy

Study design

Design

Study type: Observational invasive

Masking:	Open (masking not used)
Control:	Uncontrolled
Primary purpose:	Basic science

Recruitment

NL

Recruitment status:	Pending
Start date (anticipated):	01-10-2007
Enrollment:	100
Type:	Anticipated

Ethics review

Approved WMO

Application type:	First submission
Review commission:	METC Amsterdam UMC

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
CCMO	NL19342.018.07